Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002450 | Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients | PHASE3 | COMPLETED | 600 | — | — | - | - | Jun 24, 2005 | 61 | United States, Puerto Rico |
| NCT00002415 | Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients | PHASE2 | COMPLETED | 175 | — | — | - | - | Jun 24, 2005 | 24 | United States |
| Name | Type | Description |
|---|---|---|
| Tenofovir disoproxil fumarate | DRUG | - |
Inclusion Criteria Patients may be eligible for this study if they: * Are HIV-positive. * Have been on stable anti-HIV therapy for at least 8 weeks with no more than 4 anti-HIV drugs at the time of study entry. * Have a viral load (level of HIV in the blood) between 400 and 10,000 copies/ml. * Hav...